BioSpace News Archive

Successfully completed initial public offering on U.S. Nasdaq in February 2021, raising gross proceeds of $30 million Clinical development on track with dosing of first patient in Phase 1/2a melanoma trial of cancer vaccine EVX-02 Cash reserves of $5.8 million at December 31, 2020 plus funds from IPO provide funding for at least 12 months from the date of completion of the IPO

Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), a global biopharmaceutical company, today announced that the European Medicine Agency (EMA) Committee for Orphan Medicinal Products granted orphan drug designation for the investigational compound GLR2007

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 10:15 a.m. ET.

Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced results of a study that demonstrate in vivo efficacy, including increased median overall survival, of YTX-7739 in a mouse model for glioblastoma multiforme (GBM).

Augmedix, Inc. (OTCQX: AUGX), a leading provider of remote medical documentation and live clinical support, today announced the company will be participating in the upcoming 20th Annual Needham Virtual Healthcare Conference. Augmedix’s management is scheduled to present on Thursday, April 15, 2021 at 1:30 p.m. Eastern Time.

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter “ABL”), a South Korean biotech specializing in bispecific antibody technology, jointly announced that the first patient has been dosed in a phase 1 trial for bispecific antibody TJ-L14B/ABL50

Brattea, a leading renal denervation medical technology company in China, announced its successful completion of over $US20 million Series B+ financing led by healthcare private equity fund Kuanping Capital.

Each year the National Kidney Foundation considers the work of hundreds of specialists in the field of nephrology and selects those who most exemplify the relentless efforts of NKF to enhance the lives of patients through action, education, and accelerating change.

Clinical Ink , a global clinical trial technology company, today announced it has added its 16th concurrent Phase II/III Alzheimer’s disease study, exemplifying its ongoing commitment to this challenging therapeutic area.

Brooklyn ImmunoTherapeutics , Inc. (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the appointment of Howard J. Federoff, M.D., Ph.D., as Chief Executive Officer and President and a director as of 16 April 2021.